PharmiWeb.com - Global Pharma News & Resources
27-Mar-2019

Pet Cancer Therapeutics Market Size is Projected to Reach US$ 345.2 million by 2026 Expanding at CAGR of 10.6%

According to a new market research report "Pet Cancer Therapeutics Market (By Medicine Type: Vaccines, Chemotherapy Drugs; By Species: Dogs, Cats; By Cancer Type: Melanoma, Squamous Cell Cancer, Mast Cell Cancer, Mammary, Lymphoma) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026" published by Acumen Research and Consulting, the XYZ

The global pet cancer therapeutics market size is anticipated to around USD 345.2 million by 2026, this market is anticipated to grow with 10.6% CAGR during the forecast time period. The increasing pet healthcare expenditure is expected to drive the growth of the global pet cancer therapeutics market.

Download Sample Copy of this Report@ https://www.acumenresearchandconsulting.com/request-sample/1226

Increasing inclination of pet adoption such as dogs and cats due to the better economic status of the people will drive the pet cancer therapeutics market. Also, the increasing occurrence of pet cancer and rise in spending on healthcare of pets will stimulate the growth of the global pet cancer therapeutics market. Increase in investment in research and development initiatives to treat pet cancer will result in continuous product launch in the global market in the coming years. The key players with a strong product portfolio are estimated to expand the market share with their advanced treatments. The adverse effects of cancer drugs on pets and lack of awareness about pet diseases are the restraining factors that can hamper the market growth. The higher cost of pet cancer therapeutics will also hamper pet health in most of the developing countries across the globe. Also, the continuous launch of novel drugs for pet cancer treatment is expected to augment the global pet cancer therapeutics market.

The pet cancer vaccines are reasonably new and less used drugs than chemotherapy; thus, it is expected to grow at a high growth rate in the coming years. The dog cancer therapeutics market in the species segment is expected to hold a major share of the global pet cancer therapeutics market. Timely launch and a high number of advertised drugs for dog cancer treatment is estimated to boost the growth of the global market. Also, the dog cancer therapeutics market will grow significantly at high growth rate as compared to the cats. The presence of less number of drugs for the treatment of cancer in cats has resulted in low share. Though, with specific cat cancer medicine, the market is expected to grow significantly. Lymphoma is the most common cancer type that occurs mainly in dogs. Many pet cancer treatment providers have a strong product portfolio for the treatment of lymphoma which is projected to boost the market growth over the forecast period. However, due to the shifting attention of the companies from mast cell cancer treatment to other treatments may result in slow growth rate of mast cell cancer therapeutics market in the coming years.

Browse Full Research Report@ https://www.acumenresearchandconsulting.com/pet-cancer-therapeutics-market

The global pet cancer therapeutics market is segmented into medicine type, species, cancer type, and region. On the basis of medicine type, the global pet cancer therapeutics market is segmented into vaccines and chemotherapy drugs. On the basis of species, the global pet cancer therapeutics market is segmented into dogs and cats. On the basis of cancer type, the global pet cancer therapeutics market is segmented into melanoma, mammary, squamous cell cancer, mast cell cancer, mammary, and lymphoma. On the basis of the region, the global pet cancer therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East amp; Africa.

North America region is expected to dominate the global pet cancer therapeutics market followed by Europe region. The market in the North America region is expected to grow significantly due to the huge presence of the pet cancer therapeutics solution providers in the U.S. The pet cancer therapeutics in Europe region is anticipated to hold a significant share in the upcoming years. The demand for pet cancer therapeutics in developing countries such as India is expected to increase at a significant pace owing to the Growing awareness, accessibility of various pet cancer medicine and increasing pet healthcare spending.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

The prominent players operating in the global pet cancer therapeutics market are Aratana Therapeutics, Vetivax, Regeneus, Zoetis, AB Science, Merial, and VetDC, etc. The large players in this market hold substantial market share and have a global presence. There is a high level of competition among the players as they have targeted different pet cancers with the differentiated product offering. The continuous product launches, strategic partnerships, and geographic expansion are some of the strategies commenced by the key players to gain a competitive advantage in the global market.

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Pet Cancer Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Pet Cancer Therapeutics Market By Medicine Type
1.2.2.1. Global Pet Cancer Therapeutics Market Revenue and Growth Rate Comparison By Medicine Type (2015-2026)
1.2.2.2. Global Pet Cancer Therapeutics Market Revenue Share By Medicine Type in 2017
1.2.2.3. Vaccines
1.2.2.4. Chemotherapy Drugs
1.2.2.5. Others
1.2.3. Pet Cancer Therapeutics Market By Species
1.2.3.1. Global Pet Cancer Therapeutics Market Revenue and Growth Rate Comparison By Species (2015-2026)
1.2.3.2. Dogs
1.2.3.3. Cats
1.2.3.4. Others
1.2.4. Pet Cancer Therapeutics Market By Cancer Type
1.2.4.1. Global Pet Cancer Therapeutics Market Revenue and Growth Rate Comparison By Cancer Type (2015-2026)
1.2.4.2. Melanoma
1.2.4.3. Squamous Cell Cancer
1.2.4.4. Mast Cell Cancer
1.2.4.5. Mammary
1.2.4.6. Lymphoma
1.2.4.7. Others
1.2.5. Pet Cancer Therapeutics Market by Geography
1.2.5.1. Global Pet Cancer Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Pet Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Pet Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Pet Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Pet Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Pet Cancer Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Pet Cancer Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Pet Cancer Therapeutics Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Pet Cancer Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Pet Cancer Therapeutics Major Manufacturers in 2017

CHAPTER 4. PET CANCER THERAPEUTICS MARKET BY MEDICINE TYPE

4.1. Global Pet Cancer Therapeutics Revenue By Medicine Type
4.2. Vaccines
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Chemotherapy Drugs
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Other
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. PET CANCER THERAPEUTICS MARKET BY SPECIES

5.1. Global Pet Cancer Therapeutics Revenue By Species
5.2. Dogs
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Cats
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. PET CANCER THERAPEUTICS MARKET BY CANCER TYPE

6.1. Global Pet Cancer Therapeutics Revenue By Cancer Type
6.2. Melanoma
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Squamous Cell Cancer
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Mast Cell Cancer
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Mammary
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Lymphoma
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.7. Others
6.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA PET CANCER THERAPEUTICS MARKET BY COUNTRY

7.1. North America Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. U.S.
7.3.1. U.S. Pet Cancer Therapeutics Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE PET CANCER THERAPEUTICS MARKET BY COUNTRY

8.1. Europe Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC PET CANCER THERAPEUTICS MARKET BY COUNTRY

9.1. Asia-Pacific Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA PET CANCER THERAPEUTICS MARKET BY COUNTRY

10.1. Latin America Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST PET CANCER THERAPEUTICS MARKET BY COUNTRY

11.1. Middle East Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA PET CANCER THERAPEUTICS MARKET BY COUNTRY

12.1. Africa Pet Cancer Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Pet Cancer Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Medicine Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Species, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Cancer Type, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Aratana Therapeutics
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Vetivax
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Regeneus
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. Zoetis
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. AB Science
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Merial
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. VetDC
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Others
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1226

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report ndash;https://www.acumenresearchandconsulting.com/buy-now/0/1226

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 27-Mar-2019